SCHEMBL17599343

SCHEMBL17599343

Cc1nc(C)c(S(=O)(=O)Nc2ccc(-c3cccc(C(=O)O)c3)c3ccccc23)s1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.46
KMT2A Q03164 1/20 0.46
PFKFB4 Q16877 4/20 0.43
MCL1 Q07820 3/20 0.41
HSD11B1 P28845 1/20 0.41
PFKFB3 Q16875 3/20 0.40
BRD4 O60885 1/20 0.39
ACLY P53396 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
SERPINE1 P05121 1/20 0.38
KIT P10721 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599390 0.91 KEAP1 (0.56) KEAP1KMT2APFKFB4MCL1PFKFB3
SCHEMBL17599331 0.88 PIK3CG (0.45) KEAP1KMT2APFKFB4MCL1PFKFB3
SCHEMBL17599341 0.84 FABP4 (0.43) KEAP1KMT2APFKFB4HSD11B1PFKFB3
SCHEMBL17599388 0.79 ACLY (0.48) KMT2AMCL1BRD4ACLYAKR1C3
SCHEMBL17599312 0.79 KEAP1 (0.61) KEAP1KMT2AMCL1
SCHEMBL17599401 0.78 PFKFB4 (0.69) KEAP1PFKFB4PFKFB3
SCHEMBL17599329 0.78 KMT2A (0.55) KEAP1KMT2AMCL1BRD4ACLY
SCHEMBL17599367 0.78 PFKFB4 (0.47) KEAP1KMT2APFKFB4MCL1PFKFB3
SCHEMBL17599327 0.78 ACLY (0.61) KMT2APFKFB4MCL1BRD4ACLY
SCHEMBL17599382 0.77 WDR5 (0.45) KMT2AMCL1ACLYSERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed